Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
Authors
Keywords
-
Journal
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-10-04
DOI
10.1002/dmrr.3413
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of SGLT2 Inhibitors on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
- (2020) Baodi Xing et al. Journal of Diabetes Investigation
- Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2019) Yoshimasa Aso et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes
- (2019) Ningjian Wang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
- (2019) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Effects of Sodium Glucose Co‐transporter 2 Inhibitors on Serum Alanine Aminotransferase Values in Type 2 Diabetes Patients: A Multi‐Institutional Cohort Study
- (2019) Shih‐Chieh Shao et al. DIABETES OBESITY & METABOLISM
- Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults
- (2018) Tilman Kühn et al. BMC GASTROENTEROLOGY
- Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial
- (2018) Hiroyuki Takashima et al. Diabetes & Vascular Disease Research
- Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
- (2018) Alessandro Mantovani et al. DIABETES CARE
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study
- (2018) Yuya Tsurutani et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
- (2018) Noboru Kurinami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
- (2018) Dong Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW)
- (2018) Pia Christensen et al. DIABETES OBESITY & METABOLISM
- Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
- (2018) Teruki Miyake et al. Open Medicine
- A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
- (2018) Amedeo Lonardo et al. ACTA DIABETOLOGICA
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial
- (2017) Kanako Kato et al. EXPERT OPINION ON PHARMACOTHERAPY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
- (2017) Yuya Seko et al. JOURNAL OF GASTROENTEROLOGY
- The epidemiology of non-alcoholic fatty liver disease
- (2017) Stefano Bellentani LIVER INTERNATIONAL
- Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
- (2017) Wenjie Dai et al. MEDICINE
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
- (2016) Giuseppe Daniele et al. DIABETES CARE
- Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men
- (2016) Takuya Fukuda et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism
- (2015) Ruth C. Meex et al. Cell Metabolism
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers
- (2014) Sreeraj Macha et al. CLINICAL THERAPEUTICS
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Gamma-Glutamyltransferase Fractions in Human Plasma and Bile: Characteristic and Biogenesis
- (2014) Irene Fornaciari et al. PLoS One
- Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
- (2013) Guntram Schernthaner et al. DIABETES CARE
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis
- (2013) Ju Dong Yang et al. HEPATOLOGY
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
- (2013) J. P. H. Wilding et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)
- (2013) Siddharth Verma et al. LIVER INTERNATIONAL
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
- (2012) G. Musso et al. DIABETOLOGIA
- γ-Glutamyl transferase
- (2012) Diana Zaineff Banderas et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
- (2012) Christine Clar et al. BMJ Open
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Endpoints and clinical trial design for nonalcoholic steatohepatitis
- (2011) Arun J. Sanyal et al. HEPATOLOGY
- Human Fatty Liver Disease: Old Questions and New Insights
- (2011) J. C. Cohen et al. SCIENCE
- Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c
- (2010) P. Ferré et al. DIABETES OBESITY & METABOLISM
- Menopause impacts the relation of plasma adiponectin levels with the metabolic syndrome
- (2009) P. Henneman et al. JOURNAL OF INTERNAL MEDICINE
- Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
- (2009) John Willy Haukeland et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
- (2008) Anna Ludovica Fracanzani et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search